Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2014

View Archived Issues

Bavarian Nordic presents novel RSV vaccines

Identification of small molecules that specifically target precursor microRNAs

Stem cell epigenetic DNA methylation signature for leukemia prognosis

QIAGEN launches careHPV Test in India

Bayer plans to acquire Dihon Pharmaceutical in China

EMA accepts tedizolid phosphate MAA for review

Anacor Pharmaceuticals completes end-of-phase II meeting with the FDA for AN-2728

QLT reports data from phase Ib trial of QLT-091001

Alzheimer's Drug Discovery Foundation funds research in gene therapy

AtheroNova reports preliminary phase I date for AHRO-001

Immune Design treats first patient in phase I trial of ID-G305

Salix Pharmaceuticals and RedHill Biopharma form exclusive agreement for RHB-106

Novel DNA-damaging quinone compounds disclosed by the University of Salford

La Jolla Pharmaceutical signs agreement with George Washington University for LJPC-501

Covidien closes its acquisition of Given Imaging

EMA accepts MAA filing for oritavancin

French investigators divulge novel compounds for cancer

Investigators prepare novel nanovesicles to stimulate healing

Forest Laboratories submits NDA to FDA for nebivolol/valsartan combination

U.S. researchers disclose new EGFRvIII-derived cancer vaccines

Astellas assumes full responsibility for isavuconazole in U.S. and Canada

Takeda seeks Japanese approval for TAK-438 for acid-related diseases

Rare Disease Day News: Adaptive licensing, EryDex shows benefit in ataxia telangiectasia

Cannabidol receives FDA orphan drug status for Lennox-Gastaut syndrome

FDA grants orphan drug status to pracinostat for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...